home / stock / imv / imv news

IMV News and Press, IMV Inc. From 10/29/19

Stock Information
Company Name: IMV Inc.
Stock Symbol: IMV
Market: NASDAQ
Website: imvinfo.com
Menu
IMV IMV Quote IMV Short IMV News IMV Articles IMV Message Board
Get IMV Alerts

News, Short Squeeze, Breakout and More Instantly...
IMV - IMV Inc. to Announce Third Quarter 2019 Results and Host a Conference Call and Webcast on November 8, 2019

IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, announced today that it will hold a conference call and webcast on Friday, November 8, 2019 at 8:00 a.m. ET to dis...
IMV - IMV (IMV) Presents At Bio Investor Forum - Slideshow

The following slide deck was published by IMV Inc. in conjunction with this Read more ...

IMV - Blue Chips Join The Earnings Parade (Stocks To Watch)

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks T...

IMV - / C O R R E C T I O N From Source - IMV Inc /

In the news release issued on October 11, IMV announced that company management presentation at the BIO Investor Forum is scheduled on October 23 at 5:00 PM PST (8:00 PM EST). Please, note that the presentation and webcast are scheduled on October 23 at 2:00 PM PST (5:00 PM EST). The ...
IMV - IMV Inc. to Present at Upcoming Investor Conference

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company, today announced that company management will be attending the BIO Investor Forum to be held on October 22-23 at the Westin St. Francis, San Francisco. BIO Investor Forum and Webcast Oct. 23 5:00 PM PST A live ...

IMV - Preliminary Results From IMV's Phase 2 Basket Trial Evaluating DPX-Survivac as a Combination Therapy in Patients With Advanced and Metastatic Solid Tumors to Be Presented at ESMO Congress 2019

Tumor regressions and partial responses observed in subjects with ovarian, non-small cell lung and bladder cancer Treatment well-tolerated, with no related Grade 3-4 or immune-related adverse events IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company, t...

IMV - Preliminary Results From IMV's Phase 2 Basket Trial Evaluating DPX-Survivac as a Combination Therapy in Patients with Advanced and Metastatic Solid Tumors to Be Presented at ESMO Congress 2019

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company, today announced that preliminary results from its ongoing Phase 2 basket trial, evaluating DPX-Survivac in combination with Merck’s Keytruda® (pembrolizumab) and intermittent low dose cyclophosphamide (CPA...
IMV - IMV (IMV) Presents At 2019 Wells Fargo Healthcare Conference - Slideshow

The following slide deck was published by IMV Inc. in conjunction with this Read more ...

IMV - IMV Announces Research Collaboration with The Wistar Institute to Develop New Targeted Immunotherapy Against the Common BRAF Cancer Mutation

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage immuno-oncology company, today announced a collaboration with The Wistar Institute and Meenhard Herlyn, D.V.M., D.Sc., professor in the Molecular and Cellular Oncogenesis Program and director of Wistar’s Melanoma Research Center. U...

IMV - IMV (IMV) Presents At Canaccord Genuity 39th Growth Conference - Slideshow

The following slide deck was published by IMV Inc. in conjunction with this Read more ...

Previous 10 Next 10